|
Re: Debt
|
2
|
Zenith Epigenetics
|
Apr 04, 2022 09:48AM
|
|
Re: Biogen CTAD webcast starting now
|
2
|
Resverlogix Corp.
|
Dec 05, 2019 12:19PM
|
|
Re: Report Of Exempt Distribution.
|
2
|
Zenith Epigenetics
|
Apr 21, 2024 07:37AM
|
|
Re: RVX.WT & RVX.WT.A
|
2
|
Resverlogix Corp.
|
Dec 03, 2020 09:35AM
|
|
Re: Anybody know
|
2
|
Resverlogix Corp.
|
Apr 07, 2020 09:48AM
|
|
Re: I am asking myself....
|
2
|
Resverlogix Corp.
|
Jul 12, 2019 09:11AM
|
|
Re: IP considerations may prevent RVX from disclosing eGFR data
|
2
|
Resverlogix Corp.
|
Jun 08, 2020 06:38PM
|
|
Re: Still waiting for that BETonMACE CKD sub-study 7 months later
|
2
|
Resverlogix Corp.
|
Jun 12, 2020 01:21PM
|
|
Re: Thinking back on an older discussion and wishing we had an update - Few items
|
2
|
Resverlogix Corp.
|
Jul 24, 2020 08:17AM
|
|
Re: Option #2
|
2
|
Resverlogix Corp.
|
Sep 10, 2020 07:16PM
|
|
Re: Struggle at the opening
|
2
|
Resverlogix Corp.
|
Apr 24, 2019 10:07AM
|
|
Re: Thrown in the towel?
|
2
|
Resverlogix Corp.
|
Aug 04, 2022 08:14AM
|
|
Re: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
|
2
|
Resverlogix Corp.
|
Aug 14, 2019 10:26AM
|
|
Re: OTC Expert & Grey Market Restrictions
|
2
|
Zenith Epigenetics
|
Nov 22, 2022 10:37AM
|
|
Re: Eversana ValuationCaseStudy
|
2
|
Resverlogix Corp.
|
Jan 10, 2022 08:36AM
|
|
Re: Next private placement/licensing agreement
|
2
|
Resverlogix Corp.
|
Feb 06, 2019 03:03PM
|
|
Re: Biogen/Eisai Scrap Aducanumab
|
2
|
Resverlogix Corp.
|
Mar 22, 2019 02:19PM
|
|
Re: Rant time...
|
2
|
Resverlogix Corp.
|
Feb 05, 2021 12:00PM
|
|
Re: Biogen looks to FDA for approval of early Alzheimers drug.
|
2
|
Resverlogix Corp.
|
Oct 22, 2019 09:03AM
|
|
Re: Option #2
|
2
|
Resverlogix Corp.
|
Sep 10, 2020 07:28PM
|
